BioCentury
ARTICLE | Company News

Merck pharmaceuticals news

April 18, 2011 7:00 AM UTC

Merck's Organon N.V. subsidiary proposed to restructure and reduce headcount of R&D at Dutch sites Oss and Schaijk by 551 (53%) to 479. Organon will establish the Development Center Oss at the site with the remaining personnel, which will focus on developing formulations of existing compounds for emerging markets and all therapeutic areas. The center, which is proposed to open July 1, will also include early phase clinical research. The subsidiary submitted the proposal to its Works Council, which represents the workforce, for advice and has requested a response by May 6. ...